Anti-Proliferative Activity of Eribulin in Select Sarcoma Cell Lines
Junji Matsui, PhD, senior director, Eisai, discusses a preclinical study of eribulin (Halaven) demonstrating anti-proliferative activity in select soft tissue sarcoma cell lines.
Junji Matsui, PhD, senior director, Eisai, discusses a preclinical study of eribulin (Halaven) demonstrating anti-proliferative activity in select soft tissue sarcoma cell lines.
In this study, researchers demonstrated that eribulin showed anti-proliferative activity in xenografts of Ewing’s sarcoma, leiomyosarcoma, liposarcoma, and fibrosarcoma, Matsui explains. Additionally, the agent was found to improve tumor blood supply in a leiomyosarcoma model, which may decrease the risk of tumor metastatic potential in select soft tissue sarcomas.
The study explored morphological changes in 3 soft tissue sarcoma lines, gene expression analysis in 2 cell lines, and blood perfusion in 1 cell line. These data support the antimitotic effect and complex non-mitotic effect of eribulin in sarcoma models.
